CN100512812C - Method of extracting red indigo peucin and red indigo peucin cinnamic ester from Korean Angelica - Google Patents
Method of extracting red indigo peucin and red indigo peucin cinnamic ester from Korean Angelica Download PDFInfo
- Publication number
- CN100512812C CN100512812C CNB031364276A CN03136427A CN100512812C CN 100512812 C CN100512812 C CN 100512812C CN B031364276 A CNB031364276 A CN B031364276A CN 03136427 A CN03136427 A CN 03136427A CN 100512812 C CN100512812 C CN 100512812C
- Authority
- CN
- China
- Prior art keywords
- decursin
- radix angelicae
- angelicae sinensis
- korea
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 45
- 240000001810 Angelica gigas Species 0.000 title abstract description 6
- 235000018865 Angelica gigas Nutrition 0.000 title abstract description 6
- 150000002148 esters Chemical class 0.000 title description 2
- 235000000177 Indigofera tinctoria Nutrition 0.000 title 2
- 229940097275 indigo Drugs 0.000 title 2
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 title 2
- CUKSFECWKQBVED-INIZCTEOSA-N Decursin Chemical compound C1=CC(=O)OC2=C1C=C1C[C@H](OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-INIZCTEOSA-N 0.000 claims abstract description 136
- CUKSFECWKQBVED-UHFFFAOYSA-N Grandivittin Natural products C1=CC(=O)OC2=C1C=C1CC(OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-UHFFFAOYSA-N 0.000 claims abstract description 133
- JXZWWIMXTVJNSF-UHFFFAOYSA-N decursin Natural products CC(=CC(=O)OC1Oc2cc3OC(=O)C=Cc3cc2CC1(C)C)C JXZWWIMXTVJNSF-UHFFFAOYSA-N 0.000 claims abstract description 133
- 239000000284 extract Substances 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 130
- 238000001914 filtration Methods 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 238000001704 evaporation Methods 0.000 claims description 7
- 230000008020 evaporation Effects 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 238000009210 therapy by ultrasound Methods 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 10
- 239000007788 liquid Substances 0.000 abstract description 9
- 206010029155 Nephropathy toxic Diseases 0.000 abstract description 8
- 230000007694 nephrotoxicity Effects 0.000 abstract description 8
- 231100000417 nephrotoxicity Toxicity 0.000 abstract description 8
- 206010020772 Hypertension Diseases 0.000 abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- AGABNGOXUSXQDD-XKGFZTIGSA-N [(3s)-2,2-dimethyl-8-oxo-3,4-dihydropyrano[3,2-g]chromen-3-yl] (z)-2-methylbut-2-enoate Chemical compound C1=CC(=O)OC2=C1C=C1C[C@H](OC(=O)C(\C)=C/C)C(C)(C)OC1=C2 AGABNGOXUSXQDD-XKGFZTIGSA-N 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- AGABNGOXUSXQDD-UHFFFAOYSA-N decursinol angelate Natural products C1=CC(=O)OC2=C1C=C1CC(OC(=O)C(C)=CC)C(C)(C)OC1=C2 AGABNGOXUSXQDD-UHFFFAOYSA-N 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 38
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 33
- 239000008103 glucose Substances 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- 102000003923 Protein Kinase C Human genes 0.000 description 21
- 108090000315 Protein Kinase C Proteins 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 15
- 239000012141 concentrate Substances 0.000 description 14
- 206010018473 Glycosuria Diseases 0.000 description 11
- BGXFQDFSVDZUIW-UHFFFAOYSA-N Decursinol Natural products O1C(=O)C=CC2=C1C=C1OC(C)(C)C(O)CC1=C2 BGXFQDFSVDZUIW-UHFFFAOYSA-N 0.000 description 10
- BGXFQDFSVDZUIW-LBPRGKRZSA-N decursinol Chemical compound O1C(=O)C=CC2=C1C=C1OC(C)(C)[C@@H](O)CC1=C2 BGXFQDFSVDZUIW-LBPRGKRZSA-N 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 230000001988 toxicity Effects 0.000 description 10
- 231100000419 toxicity Toxicity 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 239000000556 agonist Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 229960005520 bryostatin Drugs 0.000 description 8
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 8
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000009188 angelicae sinensis extract Substances 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 6
- 229960004316 cisplatin Drugs 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 201000001421 hyperglycemia Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 208000001647 Renal Insufficiency Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 201000006370 kidney failure Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010059245 Angiopathy Diseases 0.000 description 4
- AGABNGOXUSXQDD-WQRDJFRPSA-N [(3s)-2,2-dimethyl-8-oxo-3,4-dihydropyrano[3,2-g]chromen-3-yl] (e)-2-methylbut-2-enoate Chemical compound C1=CC(=O)OC2=C1C=C1C[C@H](OC(=O)C(/C)=C/C)C(C)(C)OC1=C2 AGABNGOXUSXQDD-WQRDJFRPSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 231100001083 no cytotoxicity Toxicity 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 239000003005 anticarcinogenic agent Substances 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000700670 Bryozoa Species 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000007803 cold maceration Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000006680 metabolic alteration Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000003360 nephrocyte Anatomy 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- -1 phorbol chemical compound Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002423 protozoacide Substances 0.000 description 1
- 239000012492 regenerant Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Abstract
Provided are foods and pharmaceutical compositions containing Angelica gigas extract which are effective for alleviation of nephrotoxicity and diabetic hypertension. The foods and pharmaceutical compositions containing Angelica gigas extract are characterized in that they are prepared by extracting and concentrating decursin and decursinol angelate contained in the Angelica gigas, Nakai to be formulated into an oral administration form such as tablet, capsule, liquid medicine and powdered form.
Description
Technical field
The present invention relates to a kind of method of extracting decursin and Decursin angelate from Korea S's Radix Angelicae Sinensis, aforesaid extracting method is the Korea S Radix Angelicae Sinensis (Angelicagigas of Korea S with the original producton location, Nakai) as raw material, therefrom extract and to alleviate Toxicity of Kidney, suppress to belong to the renal failure disease of glycosuria complication and, to produce the food and the pharmaceutics compositions that contain aforementioned Korea S Radix Angelicae Sinensis extract then Korea S's Radix Angelicae Sinensis extract of glycosuria hypertension performance curative effect.
Background technology
Generally, Protein kinase C (PKC) is the enzyme that becomes main target in order to develop several biological active substanceies that comprise nearest anticarcinogen (carcinostatissubstance).PKC has 10 several isoezymes in animal, participate in the external signal first time of hormone or somatomedin etc. is communicated to the vital task of taking on manufacturing in intracellular a series of signal transmittance process and adjusting the cell interior second time of signal.PKC improper ground activation simultaneously after disclosing intensive carcinogen phorbol chemical compound and being the fact of PKC at intracellular host body, has enlivened by the anticarcinogen of adjusting PKC and has developed in many cancerous cell.
The BMS company of the U.S. is the material that is disclosed as activation PKC at the bryostatin of exploitation, these matter-poles contain slightly and are crying in the protozoacide of bryozoan, and exist and to take the shortcoming that waits from the ocean, also there is not chemosynthesis up to now and industry is applied flexibly difficult state.These researcheres etc. have with similar active material decursin of bryostatin and Decursin angelate by 3 years discovered during the second stage research of G7 problem, once illustrate these character and bryostatin similar (the useful PKC agonist of the project number M1-98-08-00-0021 of the Ministry of Science and Technology (decursin class)).These materials and bryostatin relatively have from the extractive advantage of plant, the intravital content of plant is 3-7% and quite high advantage, but molecular weight is little and the advantage of chemosynthesis, and the advantage that relatively toxicity is little etc. is judged as more outstanding than bryostatin thus.For the early stage industrialization of these materials should carry out being the exploitation of mass production engineering and the basic technology exploitation of industrialization as soon as possible.
Though disclosures such as this researcher and the decursin class bryostatin similarity are similar with bryostatin in nature, but have toxicity seldom, molecular weight is little and chemosynthesis, a lot of advantages that also can produce fully under the extractive situation of plant etc.And be very outstanding as the usefulness of leukemia treating agent and agent for reducing nephrotoxicity due to according to result of study decursin class, particularly to the excellent that alleviates because of the nephrotoxicity of the abuse of the injury of kidney of diabetes and heavy metal or medicine.These kidney protection effects are yet not report the new result of coming out in advanced country, and also do not form global market so far, but very big as global its marketability of kidney protective agent from now on.
If leukemic therapeutic effect is bring new hope can for the cancer patient when becoming industrialization as the usefulness of the leukemia treating agent of decursin class and agent for reducing nephrotoxicity due to; the many patients that consider to suffer from renal failure disease suffer hardships because of the kidney dialysis all one's life and during because of the required many societies of dialysis, individual's expense the kidney protection effect of decursin be the health of promoting diabetics; prevention is because of the injury of kidney of heavy metal pollution and drug dependence, and can contribute to welfare society widely by these.
The present invention relates to a kind of method of extracting decursin and Decursin angelate from Korea S's Radix Angelicae Sinensis, aforesaid extracting method is the Korea S Radix Angelicae Sinensis (Angelicagigas of Korea S with the original producton location, Nakai) as raw material, therefrom extract and to alleviate Toxicity of Kidney, suppress to belong to the renal failure disease of glycosuria complication and, to produce the food and the pharmaceutics compositions that contain aforementioned Korea S Radix Angelicae Sinensis extract then Korea S's Radix Angelicae Sinensis extract of glycosuria hypertension performance curative effect.
The original producton location of Radix Angelicae Sinensis is a Korea S, and its scope of application is a hematinic and utilizing with South Korea's medicament, is reported as decursin and the main component Decursinol that Korea S produces peculiar material recently and has effect of the blood flow of improvement and Helicobacter effect.The pure purified decursin that present inventor etc. illustrate has that nephrotoxicity suppresses and the preventive effect of the renal failure disease of glycosuria complication has been proved (PCT/KR99/00632) by zoopery.And simpler and can guarantee in a large number that the method for concentration of extracting amount makes than existing method, manufacture and can confirm when giving laboratory animal with oral taking behind the liquid in the intestinal content absorption of changing places.Decursin and Decursin angelate are that constitutional isomer is extensively known so far, and this researcher etc. have been studied its effect always and established its analytic process.Decursin is to exist with solid state in room temperature and Decursin angelate is also to exist with liquid condition at subzero 20 degree, and the analysis result of this researcher etc. is to have confirmed that the ratio of decursin and Decursin angelate is about 3:2 in Radix Angelicae Sinensis.
And, be metabolized to decursin through absorption after oral the taking and in blood, exist, so be that these compositions are absorbed in vivo easily with the oral result who takes.With existing ethanol method for extracting or the extractive Radix Angelicae Sinensis decursin of 70% ethanol method for extracting is that its amount of 35% left and right sides that accounts for concentrated solution is no more than 50%, but the result of this researcher is that its spissated amount is high and reach maximum and contain result more than 75% when using ethanol 99% or more and pharmacopeia ethanol, particularly develops in its amount Decursin angelate is separated definite method and just knows content accurately with decursin.
Summary of the invention
The objective of the invention is, in view of Radix Angelicae Sinensis extracts the fact that the decursin that contains in the concentrate and Decursin angelate can be absorbed by the body easily by oral way, can to alleviate Toxicity of Kidney, suppress to belong to the renal failure disease of glycosuria complication and in order to make to contain, provide a kind of than the existing extracting method new process for extracting of extraction decursin and Decursin angelate from Korea S's Radix Angelicae Sinensis more effectively to the food and the pharmaceutics compositions of the oral property Korea S Radix Angelicae Sinensis extract of glycosuria hypertension performance curative effect.
In order to realize aforementioned purpose, the present invention is broken into tiny to the Korea S's Radix Angelicae Sinensis powder as raw material, in the Korea S's Radix Angelicae Sinensis after the pulverizing, add ethanol, from Korea S's Radix Angelicae Sinensis, extract decursin and Decursin angelate by modes such as the temperature difference, dissolubility difference, ultrasonic sound appratus or cold-macerations then.
In addition, extracting concentrates decursin and the Decursin angelate that contains in the Radix Angelicae Sinensis, makes glycosuria hypertension and nephrotoxicity alleviated to go up available energy and the dose on the one of being grown up is characteristics for comprising 100mg to 500mg decursin and Decursin angelate.
Description of drawings
Fig. 1 is the sketch map that the result of the decursin analyzed in the Radix Angelicae Sinensis extract and Decursin angelate represents with chromatogram.RT=29.34 is meant decursin, and RT=30.84 is meant Decursin angelate, and its ratio is 3:2.
Fig. 2 is the content detection experimental result of decursin, Decursin:RT=7.84.
Fig. 3 is the content detection experimental result of decursin, Decursinol:RT=1.87.
Fig. 4 is the HPLC figure of standard Decursinol.
Fig. 5 is that matched group is at the HPLC of 0hr figure.
Fig. 6 is the HPLC figure that takes after 1 hour.
Fig. 7 is the HPLC figure that takes after 2 hours.
Fig. 8 is the HPLC figure that takes after 4 hours.
Fig. 9 is the HPLC figure that takes after 8 hours.
Figure 10 has shown that decursin is to the toxic inhibition effect of the cisplatin of LLC-PK1 cell.
Figure 11 has shown the effect of the injury of kidney that different PKC activator cause cisplatin.
Figure 12 has shown the inhibition effect of the LLC-PK1 apoptosis that decursin causes cisplatin, A) be matched group, B) be Cispiatin (CDDP) processed group, C) be decursin processed group D) be simultaneously treated group of Cispiatin and decursin.
The specific embodiment
Below, explain content of the present invention with reference to the accompanying drawings.
In following experimental example, illustration from method and the analysis result of Radix Angelicae Sinensis extracting decursin and Decursin angelate.In addition illustration be purpose pharmacy extracting concentrate and the result who absorbs post analysis blood with oral taking.Also illustration the usefulness of relevant extracting concentrate.
The manufacture method of embodiment 1 high-load decursin and Decursin angelate concentrate
1), utilizes the method for extracting of temperature difference
Separate the method that concentrates decursin and Decursin angelate from Radix Angelicae Sinensis, and utilize the Radix Angelicae Sinensis that Korea S produces and North Korea produces to implement experiment.For preparation food materials, used pharmacopeia ethanol and ethyl alcohol and used Purified Water.The Radix Angelicae Sinensis raw material with carefully pulverize below 40 orders and be dried to moisture be below 5% after, soak with pharmacopeia ethanol or ethyl alcohol (following be ethanol), add extracting 12 hours and filtration in room temperature under the state that shakes behind 2 times to 4 times of Radix Angelicae Sinensis.Decursin that contains in the concentrate of this situation and the content of Decursin angelate are 37.7%.And decursin and Decursin angelate have shown 3.92% as the Radix Angelicae Sinensis raw material.These ethanol separators are placed more than 20 hours at-20 ℃, and utilized temperature difference that the low species precipitate of dissolve with ethanol is filtered.These separator decursins and Decursin angelate are concentrated to 38.1%.Concentrate these separators and be that ethanol evaporation reclaims remaining solids more than 80 ℃ in temperature.The result who analyzes these regenerants is that decursin and Decursin angelate are 64.24%, and have possessed quite high high-load.
2), illustration utilizes the method for extracting of poor solubility
Separate the method that concentrates decursin and Decursin angelate from Radix Angelicae Sinensis, and utilize the Radix Angelicae Sinensis that Korea S produces and North Korea produces to implement experiment.For food has used Purified Water when having used pharmacopeia ethanol and ethyl alcohol and having made water.Is the Radix Angelicae Sinensis raw material that soak with pharmacopeia ethanol or ethyl alcohol (following be ethanol) back below 5% carefully to pulverize and to be dried to moisture below the 40mesh, and adds 2 times to 4 times of Radix Angelicae Sinensis under the state that shakes and room temperature extracting 12 hours and filtration.Is filtering ethanol evaporation and the remaining solids of recovery more than 80 degree in temperature.After regenerant was put into ethanol about 2 times, dissolving and ultrasonic Treatment were come complement lysis.Add the aqueous solution (0.05% tween 80) of a large amount of (alcoholic acid approximately 20 times) and collect sedimentary material obtaining alcohol layer after these filtrations.This is to have utilized purpose main constituent decursin or Decursin angelate to dissolve with ethanol and to the undissolved character of water.These are collected thing result dry and that eliminate moisture post analysis content is to have contained 76.71% decursin or Decursin angelate.This be with general extracting in contain decursin about 30% or Decursin angelate and be judged as suitable concentrate relatively the time.
3), illustration utilizes hyperacoustic method
Separate the method that concentrates decursin and Decursin angelate from Radix Angelicae Sinensis, and utilize the Radix Angelicae Sinensis that Korea S produces and North Korea produces to implement experiment.For using to food with having used pharmacopeia ethanol and ethyl alcohol.The Radix Angelicae Sinensis raw material with carefully pulverize below the 40mesh and be dried to moisture be below 5% after, extracting 12 hours in room temperature under the state that ethanol is added to 2 times to 4 times of Radix Angelicae Sinensis and shake utilizes ultrasound wave to carry out ultrasonic Treatment in 10 minutes more than 2 times in this operating process.Is these alcohol layers that filter after-filtration evaporation and the remaining solids of recovery more than 80 degree in temperature.Be this result who collects the content analysis of thing, but in the Radix Angelicae Sinensis decursin and the Decursin angelate of extracting more than 9%.This is to have shown 88% in the concentrate than the result who does not handle about 2 times decursins of Duoing of hyperacoustic method for extracting extracting and Decursin angelate in the existing Radix Angelicae Sinensis.
4), illustration utilizes the method for extracting of merceration
Separate the method that concentrates decursin and Decursin angelate from Radix Angelicae Sinensis, and utilize the Radix Angelicae Sinensis that Korea S produces and North Korea produces to implement experiment.For using to food with having used pharmacopeia ethanol and ethyl alcohol.The Radix Angelicae Sinensis raw material with carefully pulverize below the 40mesh and be dried to moisture be back below 5% ethanol added to 2 times to 4 times of Radix Angelicae Sinensis and following four days mercerations of the state that shakes after extracting.Implemented with the extractive method of heating for being utilized as comparing data in addition.Collect alcohol layer after this extract filtered and this alcohol layer volatilization ethanol and collect the residue of remaining semi-solid state in the temperature of 80 degree, the result of analysis is to be that the content of decursin and Decursin angelate is 38% and the situation of four days mercerations is to have collected 59.39% through the extractive situation of heating.
1), dissolving (emulsion form)
The extract of decursin and Decursin angelate is to be not dissolved in the water and is about 6.6mg/ml at the dissolubility in 60% ethanol, separates out and make dissolved pharmaceutical technology when high power capacity comes fluidization and homogenization so introduced.For uniform content (uniformity of content) dissolves with liquid agent after the dissolving once fully with ethanol.The 100mg decursin is made emulsifying in the aqueous solution of dissolving back pharmacy in the ethanol of 1ml, the composition of the aqueous solution of this pharmacy is the same with following illustration.These are made liquid agent with the oral purpose dilute aqueous solution of taking (3.3gram tween80,120gram HPMC, D-sorbitol 1.2kg, citric acid 30gram, Sucrarose 2.4gram, xylitol 2.4kg).Wherein citric acid is for keeping acid condition, also can using other acidic materials.These researcheres etc. were once studied decursin and Decursin angelate stable character in character of decomposing in the alkalescence and acid condition, and finally acidity were maintained to about pH3.5.
2), stability experiment
Experimental conditions is at 40 ℃, has checked the content experiment by the time in 70% relative humidity, has used high-speed liquid chromatography method (HPLC) with analytic process.Analysis result is can keep stability in acceleration environment.
Decursin: RT=7.84, as shown in Figure 2.
Decursinol:RT=1.87, as shown in Figure 3.
The result is as shown in table 1.
Table 1 stability experiment result
| Time | 0hr | 1hr | 2hr | 4hr | 8hr | 24hr | 48hr | 7day | 30day |
| Content (%) | 99.66 | 99.60 | 99.42 | 98.91 | 99.17 | 98.52 | 98.55 | 98.12 | 97.17 |
3) zoopery
(1) decursin dose (oral taking): 50mg/kg Mus
(2) with organizing number and taking the time as shown in table 2.
Table 2 is with organizing number and taking the time
| Time | 0 (matched group) | 1hr | 2hr | 4hr | 8hr |
| The group number | 5 | 5 | 5 | 5 | 5 |
* the non-matched group of taking: 5
Take test group: 20
(3) RADIX PEUCEDANI cellulose solution: decursin 100mg/ml (ethanol)
(4) take: dilution in the aqueous solution of 100mg/ml (ethanol) pharmacyization is made suspension for 10 times, and every 200g Mus is taken 1ml.
(5) analyze: take to analyze with HPLC behind the blood separation blood plasma.
Utilize experimental rat to take and confirm the oral state of taking by the time.
This is the liquid form that can orally take for being developed to, orally experimentizes after taking dissolved decursin and Decursin angelate, and the execution of experiment is to carry out in the pharmacological evaluation chamber of pharmacy university of KYUNGSUNG institution of higher education.The analysis of experimental result is to carry out in the BINEX research department.Oral once take decursin and Decursin angelate after, confirm whether to be absorbed as and analyze the Decursinol separation of serum post processing M ethanol 1ml that is easy to analyze and obtain dissolved first-class liquid and confirm experiment.
Dose and take the number as shown in table 3.
Table 3 dose and take number
| Time | 0 (matched group) | 1hr | 2hr | 4hr | 8hr |
| Article 3, | Article 4, | Article 5, | Article 5, | Article 5, | |
| Dose | 50mg/kg | 50mg/kg | 50mg/kg | 50mg/kg | 50mg/kg |
Interpretation of result:
The manufacturing of titer is to be dissolved in Decursinol 50mg in the methanol and to make 50ml.
The HPLC analysis condition is to use Hitachi HPLC, and cylinder is to use COSMOSILC18, and mobile phase is to use MeOH:H
2O=60:40, flow velocity are 1.0ml/min, and the detector wavelength is 280nm.Volume injected is 20ul.
Standard Decursinol as shown in Figure 4.
Matched group in the result of 0hr as shown in Figure 5.
Take after 1 hour the result as shown in Figure 6.
Take after 2 hours the result as shown in Figure 7.
Take after 4 hours the result as shown in Figure 8.
Take after 8 hours the result as shown in Figure 9.
The result separates Decursinol in RT3.24.Absorb that decursin decomposes in vivo later on and the decomposition of confirming Decursinol, the material of the also almost non-toxic property of Decursinol oneself can be thought and not have toxicity problem because of metabolite.Confirm the absorption after oral the taking thus.
The structure of decursin is suc as formula shown in the I.
Formula I
The structure of Decursin angelate is suc as formula shown in the II.
Formula II
The usefulness experiment of embodiment 3 decursins and Decursin angelate to the glycosuria disease
The cause of disease of the angiopathy of glycosuria is very complicated, and hyperglycemia has become to cause the most important factor of angiopathy in many metabolic alterations of diabetes.The increase that the vascular smooth muscle cell that hyperglycemia causes (VSMC) is grown up causes arteriosclerosis or hypertension.But pass on mechanism not clear with hyperglycemia and the associated signal of angiopathy.Hyperglycemia increases diglyceride (DAG), the increase of DAG and activation Protein kinase C (PKC) approach is reported as hyperglycemia generation angiopathy.Think thus the material that seek to suppress the PKC signal pathway be in the good method of treatment or prevention glycosuria complication one of.So studied with pkc inhibitor in the meantime many, but the toxicity of pkc inhibitor its oneself has become problem with no specificity.
Decursin is the PKC agonist as the Radix Angelicae Sinensis extract, stops the propagation of cancerous cell, differently is reported as the control down quickly the PKC of activation with the Buddhist ripple ester of the PKC agonist of brute force.So in this experiment to whether by decursin stop the propagation that causes the VSMC that high glucose causes in the body with it with and prevention mechanism study.
Whether affirmation increases the growth of the A10 cell in the vascular smooth muscle cell according to concentration of glucose, for the state of optimization hyperglycemia is cultivated the A10 cell in different concentration of glucose.With 1 X 10
3Cell/ml is inoculated in the 96 hole flat boards, after 16 hours with 5,10,20,30,40, the culture medium of 50mM D-concentration of glucose, change after 72 hours and measure the survivaling cell number with MTT assay.The propagation of A10 cell is to increase significantly according to the increase of concentration of glucose after 72 hours.Cell proliferation in 50mM D-glucose increases to 15% approximately than 5.5mM D-glucose.
General common glucose be 5.5mM D-glucose and high glucose to be to use the 25mMD-glucose be more, difference high glucose use 30mM D-glucose in this experiment in order to strengthen common glucose and high glucose.With 3 X 10
3The A10 cell inoculation in 6 hole flat boards, was changed culture medium with 5.5mM D-glucose and 30mM D-glucose later in 16 hours.Cell culture five days is used trypan blue (trypan blue) dyeing calculating survivaling cell number every day.Cultured cells shows more longways than cultured cells in common glucose in high glucose, and the result is longer for about about 20% than the cell in common glucose at the cell in the high glucose.
Be the effect of the decursin of investigation in the A10 cell proliferation that is caused by high glucose, handle the decursin (1,5,10,25mM) of variable concentrations in the A10 cell, calculate after three days.The situation that decursin 25mM is handled in common glucose and high glucose is the propagation that all stops cells than the matched group of not handling decursin about about 20%.Handle 5 in the high glucose, the control level of no cytotoxicity stops propagation the 25mM decursin time.In order to confirm that whether decursin has cytotoxicity still to stop the propagation of cell, measures the quantity of living cells and dead cell respectively.Living cells is more than 98% when consequently handling decursin.Generally speaking, do not influence the growth of cell when in common glucose, handling decursin, and no cytotoxicity ground stops cell proliferation according to concentration when handling in high glucose.Show Decursin angelate and Decursinoltiglate better effects if than decursin.In order to confirm its effect again, handling 1,5,10 in the A10 cell, behind the Decursin angelate and Decursinol tiglate of 25mM, after three days, calculating with trypan blue.Decursin angelate and Decursinol tiglate do not influence the growth of cell in common glucose, and stop cell proliferation high glucose Rigen according to concentration.Decursin angelate 25mM is at common glucose, all stops about cell proliferation of about 20% in the high glucose, but 5 and 10mM be that no cytotoxicity ground stops cell proliferation in high glucose.Decursinol tiglate is that thing cytotoxicity ground stops the cell proliferation that is caused by high glucose according to concentration in common glucose.
The nephrotoxicity of the ciplatin of embodiment 4 decursins alleviates effect
In order to investigate the decursin that ciplatin that nephrotoxicity according to the ciplatin of decursin alleviates effect and 50uM handles variable concentrations together.Investigated the death of cell in 24 hours with the quantity of confirming flow cell with the discharging amount of " Invest, Then Investigate " LDH.As shown in figure 10, the increase according to decursin concentration increases the existence cell quantity.This is can confirm by the quantity minimizing of LDH amount minimizing of emitting and flow cell.
For whether the protection effect of confirming these decursins is the effect of PKC agonist, use different PKC agonist to confirm that the toxicity of cisplatin alleviates effect.With the synthetic DAG of PMA, also use the toxicity of coming result of experiment not observe cispiatin (CDDP) to alleviate effect with the next cognitive bryostatin of the PKC agonist of uniqueness with the next cognition of tumor promotor.Alleviating effect according to the cispiatin toxicity of decursin as can be known from these results has with the PKC agonist irrelevant.PKC is that the protein that plays an important role in the cell growth and these results are that the cytotoxicity of prompting cispiatin is different with the signal reception and registration process of general cell, as shown in figure 11.
For nephrocyte protection effect and the FACS that confirms decursin implements electrophoresis.Utilize the result of bonded oddly propidium iodide enforcement FACS on the DNA to be, obtained suppressing the result of the cell death that taken place by cisplatin, the result of DNA in the electrophoretic cell is the dna ladder degree that reduces as withered labelling, as shown in figure 12, see that thus decursin prevents the result of Apotosis.
Suppress the Cytotoxic effect that cisplatin causes by confirming that as above-mentioned experimental result decursin has.And the activity of these decursins is to follow with the PKC agonist to come the cognitive different effect of decursin to cause.
Embodiment 5
The result who utilizes Radix Angelicae Sinensis to concentrate that the extract pharmacy becomes liquid agent and the decursin of 300mg and Decursin angelate one time on the one or three times on the one components were taken in everyone one day is that the color that obtains urinating in the variation of patient's states becomes the result that the stink of clear and urine disappears.Also having 300mg on the one to take to be the result of twice on the one or three times is that the phenomenon that causes dropping obtains the more estimation result of dose.Be judged as 300mg on the one thus one time or twice on the one 150mg for well.
When extracting with existing general extracting method, decursin and Decursin angelate content in the final extract are that its amount of 35% left and right sides is no more than 50%.When using extracting method of the present invention in Korea S's Radix Angelicae Sinensis, to extract decursin and Decursin angelate, decursin and Decursin angelate content in the final extract are: the extracting method based on the temperature difference can obtain 64.24% content, extracting method based on dissolubility difference can obtain 76.71% content, extracting method based on ultrasonic Treatment can obtain 88% content, can obtain 59.39% content based on the extracting method of merceration method.This shows, ought be classified as primary raw material with Korea S, when producing the food that contains the quantitative decursin that can bring into play remarkable effect and Decursin angelate and pharmaceutics compositions, extracting method of the present invention can extract decursin and Decursin angelate very effectively from Korea S's Radix Angelicae Sinensis.
Claims (4)
1. a method of extracting decursin and Decursin angelate from Korea S's Radix Angelicae Sinensis comprises the following steps:
Korea S's Radix Angelicae Sinensis powder is broken into thin piece below 40 meshes, makes it be dried to moisture less than 5% state, add the ethanol of 2 ~ 4 times of amounts that are equivalent to Korea S's Radix Angelicae Sinensis on the Korea S's Radix Angelicae Sinensis after the pulverizing, 12 hours after-filtration and quantitative step are extracted in vibration; Ethanol separator after the aforementioned filtration was quantitatively placed 20 hours under subzero 20 ℃ environment, utilized the temperature difference to make and be insoluble in alcoholic acid species precipitate and filter the step that the ethanol separator is extracted in the back; Under 80 ℃ environment, make the ethanol evaporation of aforementioned ethanol separator and reclaim the step of all the other solid constituents.
2. a method of extracting decursin and Decursin angelate from Korea S's Radix Angelicae Sinensis comprises the following steps:
Korea S's Radix Angelicae Sinensis powder is broken into thin piece below 40 meshes, makes it be dried to moisture less than 5% state, add the ethanol of 2 ~ 4 times of amounts that are equivalent to Korea S's Radix Angelicae Sinensis on the Korea S's Radix Angelicae Sinensis after the pulverizing, 12 hours after-filtration and quantitative step are extracted in vibration; The ethanol evaporation of the ethanol separator after making aforementioned filtration quantitatively under 80 ℃ the environment also reclaims the step of all the other solid constituents; The ethanol that adds 2 times of amounts at the solid constituent that reclaims is also dissolved, then by the further dissolved step of ultrasonic Treatment; Filter aforementioned solute and collect alcohol layer, the amount of adding the aqueous solution contain tween 800.05% and aqueous solution then is equivalent to 20 times of amount of alcohol, makes its dry and dewatered step after collecting deposit.
3. a method of extracting decursin and Decursin angelate from Korea S's Radix Angelicae Sinensis comprises the following steps:
Korea S's Radix Angelicae Sinensis powder is broken into thin piece below 40 meshes, make it be dried to moisture less than 5% state, on the Korea S's Radix Angelicae Sinensis after the pulverizing, add the ethanol of 2 ~ 4 times of amounts that are equivalent to Korea S's Radix Angelicae Sinensis, vibration was extracted 12 hours, used ultrasonic sound appratus to carry out the step of twice 10 minutes ultrasonic Treatment in leaching process; In the ethanol evaporation that makes the ethanol separator after extracting, filter quantitatively by aforementioned ultrasonic Treatment under 80 ℃ the environment and reclaim the step of all the other solid constituents.
4. a method of extracting decursin and Decursin angelate from Korea S's Radix Angelicae Sinensis comprises the following steps:
Korea S's Radix Angelicae Sinensis powder is broken into thin piece below 40 meshes, makes it be dried to moisture, on the Korea S's Radix Angelicae Sinensis after the pulverizing, add the ethanol of 2 ~ 4 times of amounts that are equivalent to Korea S's Radix Angelicae Sinensis, vibration merceration and the step of in four day time, being extracted less than 5% state; Filter aforementioned extract and collect alcohol layer, under 80 ℃ environment, make ethanol evaporation then and reclaim the step of semi-solid phase residuals.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2003-0016220A KR100509843B1 (en) | 2003-03-14 | 2003-03-14 | Method of extraction decursin and decursinol angelate from Angelica gigas, Nakai |
| KR200316220 | 2003-03-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1530100A CN1530100A (en) | 2004-09-22 |
| CN100512812C true CN100512812C (en) | 2009-07-15 |
Family
ID=34309371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031364276A Expired - Fee Related CN100512812C (en) | 2003-03-14 | 2003-05-19 | Method of extracting red indigo peucin and red indigo peucin cinnamic ester from Korean Angelica |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR100509843B1 (en) |
| CN (1) | CN100512812C (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101072175B1 (en) * | 2004-06-22 | 2011-10-10 | 최백희 | Compositions for the urinary dysfuction and edema containing decursin and/or decursinol angelate, or angelica extract containing decursin and/or decursinol angelate |
| KR100775741B1 (en) | 2006-02-22 | 2007-11-09 | (주)에이지아이 | A method for the preparation of extract from Angelica gigantis radix and the composition containing the extract |
| KR100777060B1 (en) * | 2006-02-22 | 2007-11-28 | 전남대학교산학협력단 | Method for distinguishing species of from flavor components using solvent free solid injector mounted gas chromatography |
| CN100424086C (en) * | 2006-07-24 | 2008-10-08 | 长沙高新技术产业开发区博海生物科技有限公司 | Production method of decursin |
| CN100368806C (en) * | 2006-07-24 | 2008-02-13 | 中南大学 | Decursin detection method |
| KR100758550B1 (en) * | 2006-08-14 | 2007-09-13 | 학교법인 포항공과대학교 | Method for increasing productivity of decursin or decursinol angelate by treatment with elicitor in angelica gigas nakai |
| KR100893779B1 (en) * | 2007-05-10 | 2009-04-20 | 인제대학교 산학협력단 | The extracting method of Angelica gigas Nakai that has effect of scavenging action on free radical |
| CN102150682B (en) * | 2011-03-02 | 2013-03-20 | 江苏省中国科学院植物研究所 | Application of decursin as agricultural insecticide |
| CN102552518A (en) * | 2011-12-31 | 2012-07-11 | 沈阳药科大学 | Application of four traditional Chinese medicines in relieving liver and kidney toxicity |
| US20150104398A1 (en) * | 2013-10-10 | 2015-04-16 | International Flavors & Fragrances Inc. | Taste modulator and method of use thereof |
| KR101658350B1 (en) | 2015-02-06 | 2016-09-30 | 경성대학교 산학협력단 | Pharmaceutical Composition For Treating Hyperlipidaemia |
| KR102556971B1 (en) | 2017-01-03 | 2023-07-19 | 주식회사 다산제약 | A new synthesis method of (+)-Decursinol |
| KR102500887B1 (en) * | 2020-06-17 | 2023-02-23 | 주식회사 에버그린바이오 | Manufacturing method of fraction comprising decursin and decursinol angelate |
| KR20220102354A (en) * | 2021-01-13 | 2022-07-20 | 경성대학교 산학협력단 | Composition for Preventing or Treating of Disease Caused by Hyper-proliferation of Vascular Smooth Muscle Cell Comprising Decursinol as Active Ingredient |
-
2003
- 2003-03-14 KR KR10-2003-0016220A patent/KR100509843B1/en not_active IP Right Cessation
- 2003-05-19 CN CNB031364276A patent/CN100512812C/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 重齿毛当归化学成分的研究. 柳江华，陈玉萍，徐绥绪，姚新生，谭严.中草药，第6期. 1996 |
| 重齿毛当归化学成分的研究. 柳江华，陈玉萍，徐绥绪，姚新生，谭严.中草药，第6期. 1996 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040080854A (en) | 2004-09-20 |
| KR100509843B1 (en) | 2005-08-24 |
| CN1530100A (en) | 2004-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100512812C (en) | Method of extracting red indigo peucin and red indigo peucin cinnamic ester from Korean Angelica | |
| CN103319479B (en) | Rhubarb yellow berberine ion-pair compound, preparation method and application | |
| CN103037879A (en) | Method for preparing novel processed ginseng or an extract thereof, the usually minute ginsenoside content of which is increased | |
| CN101307038B (en) | 4- benzyl piperazi ethyliminumacyl (formimidoyl benzol)hydrazine compounds, preparation method thereof, pharmaceutical compositions and use | |
| CN102423346A (en) | Tree peony root bark extract, as well as preparation method and application thereof | |
| CN101423558B (en) | Eupatorium adenophorum spreng polysaccharide and preparation method and use | |
| CN101336964A (en) | Mulberry bark extract capable of reducing blood sugar and preparation method thereof | |
| CN101468061B (en) | Extract of immature exocarp of Juglans mandshurica Maxim., preparation method and medical use | |
| CN103340880B (en) | Application of 2,3-dihydroxy benzoic acid ester compound in preparation of foods and medicines for treating diabetes | |
| CN101152234B (en) | Application of cortex eucommiae lignans and its extract in against cardiovascular reconstruction | |
| CN101367802B (en) | Beta-kabarin alkaloids in quassia wood, preparation method and application thereof | |
| CN101700367B (en) | Pharmaceutical composition for treating diseases of urinary system | |
| CN1919258B (en) | Application of schisandra chinensis in the preparation of medicine for preventing and reducing toxic and side effect of antitumor agent | |
| CN100427099C (en) | Juglans mandshurica maxim pdysaccharide preparation capable of effectively treating brain cancer and its preapring method | |
| CN100490850C (en) | Application of magnolia vine fruit in preparation of anti-tumor medicine or multi-medicine tolerant reversal agent | |
| CN103804392A (en) | Two terphenylzidioxazine derivatives and applications thereof | |
| CN103800389A (en) | Hypoglycemic active ingredient in Sarcodon leucopus and preparation method and application thereof | |
| CN102988525A (en) | Preparation method for total lignans in hawthorn seeds, and novel application | |
| CN114632102B (en) | Application and preparation method of plantain waste plant extract | |
| CN113577130B (en) | Histidine dipeptide composition for repairing liver injury and application thereof | |
| CN101869604B (en) | Preparation method and application of cortex meliae effective ingredients | |
| CN101869588B (en) | Preparation method and application of effective component of chrysanthemum | |
| CN107496547A (en) | One kind suppresses the garden burnet crude extract and preparation method of classical Wnt/β catenin paths | |
| CN101856375B (en) | Preparation method and application of effective component of trumpetcreeper | |
| CN102631418B (en) | Antiphlogistic and analgesic traditional Chinese medicine extract and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090715 Termination date: 20130519 |